[HTML][HTML] Mechanisms of antibiotic resistance in Pseudomonas aeruginosa biofilms

M Fernández-Billón, AE Llambías-Cabot… - Biofilm, 2023 - Elsevier
Pseudomonas aeruginosa is a major cause of life-threatening acute infections and life-long
lasting chronic infections. The characteristic biofilm mode of life in P. aeruginosa chronic …

An in vitro dynamic bioreactor model for evaluating antimicrobial effectiveness on periodontal polymicrobial biofilms: a proof‐of‐concept study

SS Ramachandra, FB Sime, S Naicker… - Journal of …, 2024 - Wiley Online Library
Background The aim of this study was to investigate an in vitro dynamic bioreactor model by
evaluating the antimicrobial effect of clinically relevant amoxicillin doses on polymicrobial …

Ceftolozane-tazobactam against Pseudomonas aeruginosa cystic fibrosis clinical isolates in the hollow-fiber infection model: challenges imposed by hypermutability …

JR Tait, M Harper, S Cortés-Lara… - Antimicrobial Agents …, 2023 - Am Soc Microbiol
Pseudomonas aeruginosa remains a challenge in chronic respiratory infections in cystic
fibrosis (CF). Ceftolozane-tazobactam has not yet been evaluated against multidrug …

Evaluation of meropenem‐ciprofloxacin combination dosage regimens for the pharmacokinetics of critically ill patients with augmented renal clearance

AA Agyeman, KE Rogers, JR Tait… - Clinical …, 2021 - Wiley Online Library
Augmented renal clearance (ARC, creatinine clearance> 130 mL/minute) makes difficult
achievement of effective concentrations of renally cleared antibiotics in critically ill patients …

Simulated intravenous versus inhaled tobramycin with or without intravenous ceftazidime evaluated against hypermutable Pseudomonas aeruginosa via a dynamic …

H Bilal, JR Tait, Y Lang, J Zhou, PJ Bergen… - Antimicrobial Agents …, 2022 - Am Soc Microbiol
Acute exacerbations of chronic respiratory infections in patients with cystic fibrosis are highly
challenging due to hypermutable Pseudomonas aeruginosa, biofilm formation and …

[HTML][HTML] Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model …

SKJ Breen, M Harper, C López-Causapé… - International journal of …, 2024 - Elsevier
Abstract Objective Hypermutable Pseudomonas aeruginosa strains are highly prevalent in
chronic lung infections of patients with cystic fibrosis (CF). Acute exacerbations of these …

Clinically Relevant Concentrations of Polymyxin B and Meropenem Synergistically Kill Multidrug-Resistant Pseudomonas aeruginosa and Minimize Biofilm Formation

H Wickremasinghe, HH Yu, MAK Azad, J Zhao… - Antibiotics, 2021 - mdpi.com
The emergence of antibiotic resistance has severely impaired the treatment of chronic
respiratory infections caused by multidrug-resistant (MDR) Pseudomonas aeruginosa. Since …

Efficacy of meropenem extended infusion vs intermittent bolus monotherapy and in combination with colistin against Pseudomonas aeruginosa biofilm

E Benavent, M Ulldemolins, C El Haj… - International Journal of …, 2023 - Elsevier
Introduction Device-related infections are difficult to treat due to biofilms. In this setting,
optimizing antibiotic efficacy is difficult as most pharmacokinetic/pharmacdynamic (PK/PD) …

Antibiotic Resistance Development in Bacterial Biofilms

MD Macià, A Oliver - … Strategies: Current and Future Applications to …, 2022 - Springer
Biofilms are organized bacterial communities embedded in an extracellular polymeric matrix
attached to living or abiotic surfaces or forming aggregates. This mode of growth is …

YgfB–ein potentieller Regulator der ß-Laktamresistenz in einem multiresistenten Stamm von P. aeruginosa

EJ Walter - 2024 - ub01.uni-tuebingen.de
Pseudomonas aeruginosa (Pa) ist ein Gram-negatives Bakterium, welches vor allem
nosokomiale Infektionen wie Pneumonie oder Sepsis verursacht. Ebenso bei Patienten mit …